Childhood acute lymphoblastic leukemia: Integrating genomics into therapy

Cancer

Volumn 121, Issue 20, 2015, Pages 3577-3590

  Tasian, Sarah K ^a,b   Loh, Mignon L ^c,d   Hunger, Stephen P ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

acute lymphoblastic leukemia; cytogenetics; genomics; pediatrics; therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; NEW DRUG; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEUPLOIDY; CANCER RISK; CANCER THERAPY; CAUSE OF DEATH; CHILDHOOD LEUKEMIA; CHILDHOOD MORTALITY; CHROMOSOME 21; CHROMOSOME TRANSLOCATION; DISEASE COURSE; EPIGENETICS; GENE; GENE DELETION; GENE MUTATION; GENETIC PREDISPOSITION; GENOMICS; HUMAN; LEUKEMIA RELAPSE; NONHUMAN; NOTCH1 GENE; PRIORITY JOURNAL; REVIEW; TRISOMY 21; X CHROMOSOME; ADOLESCENT; CHILD; GENETICS; INFANT; MOLECULARLY TARGETED THERAPY; MUTATION; PERSONALIZED MEDICINE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROCEDURES;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; INFANT; MOLECULAR TARGETED THERAPY; MUTATION; PRECISION MEDICINE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84943583161     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29573     Document Type: Review

References (138)

1. Pui CH,. Recent advances in acute lymphoblastic leukemia. Oncology. 2011; 25: 341, 346-347.
2. Hunger SP, Lu X, Devidas M, et al., Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30: 1663-1669.
3. Pui CH, Mullighan CG, Evans WE, Relling MV,. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012; 120: 1165-1174.
4. Smith M, Arthur D, Camitta B, et al., Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996; 14: 18-24.
5. Borowitz MJ, Devidas M, Hunger SP, et al., Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008; 111: 5477-5485.
6. Hunger SP, Loh ML, Whitlock JA, et al., Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013; 60: 957-963.
7. Pui CH, Pei D, Coustan-Smith E, et al., Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 2015; 16: 465-474.
8. Nguyen K, Devidas M, Cheng SC, et al., Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008; 22: 2142-2150.
9. Vardiman JW, Thiele J, Arber DA, et al., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114: 937-951.
10. Perez-Andreu V, Xu H, Yang JJ,. The novel susceptibility variants for childhood acute lymphoblastic leukemia. J Natl Cancer Inst. 2013; 105: 1512-1513.
11. Xu H, Yang W, Perez-Andreu V, et al., Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst. 2013; 105: 733-742.
12. Shah S, Schrader KA, Waanders E, et al., A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013; 45: 1226-1231.
13. Perez-Andreu V, Roberts KG, Xu H, et al., A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood. 2015; 125: 680-686.
14. Zhang MY, Churpek JE, Keel SB, et al., Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015; 47: 180-185.
15. Noetzli L, Lo RW, Lee-Sherick AB, et al., Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015; 47: 535-538.
16. Harrison CJ, Haas O, Harbott J, et al., Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfurt-Munster study group. Br J Haematol. 2010; 151: 132-142.
17. Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ,. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010; 115: 206-214.
18. Moricke A, Reiter A, Zimmermann M, et al., Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008; 111: 4477-4489.
19. Vora A, Goulden N, Wade R, et al., Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013; 14: 199-209.
20. Pui CH, Williams DL, Raimondi SC, et al., Hypodiploidy is associated with a poor prognosis in childhood acute lymphoblastic leukemia. Blood. 1987; 70: 247-253.
21. Heerema NA, Nachman JB, Sather HN, et al., Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 1999; 94: 4036-4045.
22. Devidas M, Raetz EA, Loh ML, et al., Outcome for children with hypodiploid acute lymphoblastic leukemia (ALL) on contemporary Children's Oncology Group (COG) clinical trials [abstract]. Pediatr Blood Cancer. 2013; 60. Abstract O0036. PMID: 17473063.
23. Nachman JB, Heerema NA, Sather H, et al., Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood. 2007; 110: 1112-1115.
24. Harrison CJ, Moorman AV, Broadfield ZJ, et al., Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol. 2004; 125: 552-559.
25. Soverini S, De Benedittis C, Papayannidis C, et al., Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014; 120: 1002-1009.
26. Mehta PA, Eapen M, Zhang M-J, et al., Transplant outcomes for children with hypodiploid acute lymphoblastic leukemia: the CIBMTR experience [abstract]. Biol Blood Marrow Transplant. 2014; 20: S87.
27. Holmfeldt L, Wei L, Diaz-Flores E, et al., The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013; 45: 242-252.
28. Parker H, An Q, Barber K, et al., The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1. Genes Chromosomes Cancer. 2008; 47: 1118-1125.
29. Mori H, Colman SM, Xiao Z, et al., Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci U S A. 2002; 99: 8242-8247.
30. Greaves M,. Darwin and evolutionary tales in leukemia. The Ham-Wasserman Lecture. Hematology Am Soc Hematol Educ Program. 2009; 2009: 3-12.
31. Raimondi SC, Behm FG, Roberson PK, et al., Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J Clin Oncol. 1990; 8: 1380-1388.
32. Pui CH, Raimondi SC, Hancock ML, et al., Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23; p13) or its derivative. J Clin Oncol. 1994; 12: 2601-2606.
33. Felice MS, Gallego MS, Alonso CN, et al., Prognostic impact of t(1;19)/TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Munster-based protocols. Leuk Lymphoma. 2011; 52: 1215-1221.
34. Jeha S, Pei D, Raimondi SC, et al., Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia. 2009; 23: 1406-1409.
35. Hunger SP,. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood. 1996; 87: 1211-1224.
36. Mullighan CG,. Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest. 2012; 122: 3407-3415.
37. Collins EC, Rabbitts TH,. The promiscuous MLL gene links chromosomal translocations to cellular differentiation and tumour tropism. Trends Mol Med. 2002; 8: 436-442.
38. Muntean AG, Hess JL,. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol. 2012; 7: 283-301.
39. Ford AM, Ridge SA, Cabrera ME, et al., In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature. 1993; 363: 358-360.
40. Gale KB, Ford AM, Repp R, et al., Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A. 1997; 94: 13950-13954.
41. Pieters R, Schrappe M, De Lorenzo P, et al., A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007; 370: 240-250.
42. Dreyer ZE, Hilden JM, Jones TL, et al., Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (cohort 3). Pediatr Blood Cancer. 2015; 62: 419-426.
43. Pui CH, Chessells JM, Camitta B, et al., Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia. 2003; 17: 700-706.
44. Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D,. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood. 2005; 105: 812-820.
45. Stam RW, den Boer ML, Schneider P, et al., Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood. 2005; 106: 2484-2490.
46. Stam RW, Schneider P, de Lorenzo P, Valsecchi MG, den Boer ML, Pieters R,. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia. Blood. 2007; 110: 2774-2775.
47. Annesley CE, Brown P,. The biology and targeting of FLT3 in pediatric leukemia [serial online]. Front Oncol. 2014; 4: 263.
48. Bernt KM, Armstrong SA,. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology Am Soc Hematol Educ Program. 2011; 2011: 354-360.
49. Dobbins SE, Sherborne AL, Ma YP, et al., The silent mutational landscape of infant MLL-AF4 pro-B acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2013; 52: 954-960.
50. Andersson AK, Ma J, Wang J, et al., The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015; 47: 330-337.
51. Arico M, Valsecchi MG, Camitta B, et al., Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000; 342: 998-1006.
52. Arico M, Schrappe M, Hunger SP, et al., Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010; 28: 4755-4761.
53. Biondi A, Schrappe M, De Lorenzo P, et al., Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012; 13: 936-945.
54. Schultz KR, Bowman WP, Aledo A, et al., Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol. 2009; 27: 5175-5181.
55. Schultz KR, Carroll A, Heerema NA, et al., Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia. 2014; 28: 1467-1471.
56. Chang BH, Willis SG, Stork L, et al., Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. Br J Haematol. 2012; 157: 507-510.
57. van der Veer A, Zaliova M, Mottadelli F, et al., IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood. 2014; 123: 1691-1698.
58. Olsson L, Johansson B,. Ikaros and leukaemia. Br J Haematol. 2015; 169: 479-491.
59. Dorge P, Meissner B, Zimmermann M, et al., IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2013; 98: 428-432.
60. Martinelli G, Iacobucci I, Storlazzi CT, et al., IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 2009; 27: 5202-5207.
61. Moorman AV, Robinson H, Schwab C, et al., Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials. J Clin Oncol. 2013; 31: 3389-3396.
62. Heerema NA, Carroll AJ, Devidas M, et al., Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk Children's Oncology Group studies: a report from the Children's Oncology Group. J Clin Oncol. 2013; 31: 3397-3402.
63. Harrison CJ, Moorman AV, Schwab C, et al., An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia. 2014; 28: 1015-1021.
64. Li Y, Schwab C, Ryan SL, et al., Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature. 2014; 508: 98-102.
65. Izraeli S, Vora A, Zwaan CM, Whitlock J,. How I treat ALL in Down's syndrome: pathobiology and management. Blood. 2014; 123: 35-40.
66. Maloney KW, Carroll WL, Carroll AJ, et al., Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood. 2010; 116: 1045-1050.
67. Lundin C, Forestier E, Klarskov Andersen M, et al., Clinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries [serial online]. J Hematol Oncol. 2014; 7: 32.
68. Buitenkamp TD, Izraeli S, Zimmermann M, et al., Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014; 123: 70-77.
69. Russell LJ, Capasso M, Vater I, et al., Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009; 114: 2688-2698.
70. Mullighan CG, Collins-Underwood JR, Phillips LA, et al., Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009; 41: 1243-1246.
71. Bercovich D, Ganmore I, Scott LM, et al., Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet. 2008; 372: 1484-1492.
72. Kearney L, Gonzalez De Castro D, Yeung J, et al., Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood. 2009; 113: 646-648.
73. Zhang J, Mullighan CG, Harvey RC, et al., Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011; 118: 3080-3087.
74. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al., A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009; 10: 125-134.
75. Mullighan CG, Su X, Zhang J, et al., Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; 360: 470-480.
76. Harvey RC, Mullighan CG, Wang X, et al., Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010; 116: 4874-4884.
77. Mullighan CG, Miller CB, Radtke I, et al., BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008; 453: 110-114.
78. Loh ML, Zhang J, Harvey RC, et al., Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood. 2013; 121: 485-488.
79. van der Veer A, Waanders E, Pieters R, et al., Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013; 122: 2622-2629.
80. Boer JM, Koenders JE, van der Holt B, et al., Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates [published online ahead of print March 13, 2015]. Haematologica. doi: 10.3324/haematol.2014.117424.
81. Roberts KG, Pei D, Campana D, et al., Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol. 2014; 32: 3012-3020.
82. Roberts KG, Li Y, Payne-Turner D, et al., Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014; 371: 1005-1015.
83. Roberts KG, Morin RD, Zhang J, et al., Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012; 22: 153-166.
84. Harvey RC, Mullighan CG, Chen IM, et al., Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010; 115: 5312-5321.
85. Attarbaschi A, Morak M, Cario G, et al., Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. Br J Haematol. 2012; 158: 772-777.
86. Ensor HM, Schwab C, Russell LJ, et al., Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood. 2011; 117: 2129-2136.
87. Maude SL, Tasian SK, Vincent T, et al., Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2012; 120: 3510-3518.
88. Weston BW, Hayden MA, Roberts KG, et al., Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol. 2013; 31: e413-e416.
89. Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E,. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica. 2013; 98: e146-e148.
90. Schwab C, Andrews R, Chilton L, et al., EBF1-PDGFRB fusion in paediatric acute lymphoblastic leukaemia (ALL): genetic profile and clinical implications [abstract]. Blood. 2014; 124: Abstract 1068.
91. Harvey RC, Kang H, Roberts KG, et al., Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B-precursor acute lymphoblastic leukemia (ALL) patients with a Philadelphia chromosome-like signature ("Ph-like" or "BCR-ABL1-like") for therapeutic targeting and clinical intervention [abstract]. Blood. 2013; 122 (suppl 21). Abstract 826.
92. Zaliova M, Zimmermannova O, Dorge P, et al., ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia. 2014; 28 182-185.
93. Clappier E, Auclerc MF, Rapion J, et al., An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia. 2014; 28: 70-77.
94. Pui C, Robison L, Look A,. Acute lymphoblastic leukaemia. Lancet. 2008; 371: 1030-1043.
95. Wood BL, Winter SS, Dunsmore KP, et al., T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children's Oncology Group (COG) study AALL0434 [abstract]. Blood. 2014; 123. Abstract 1.
96. 9/L) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group. Br J Haematol. 2015; 168: 533-546.
97. Berg SL, Blaney SM, Devidas M, et al., Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005; 23: 3376-3382.
98. Gokbuget N, Basara N, Baurmann H, et al., High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011; 118: 3504-3511.
99. Dunsmore KP, Devidas M, Linda SB, et al., Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30: 2753-2759.
100. Winter SS, Dunsmore KP, Devidas M, et al., Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015; 62: 1176-1183.
101. Ferrando AA, Neuberg DS, Staunton J, et al., Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002; 1: 75-87.
102. Meijerink JP,. Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2010; 23: 307-318.
103. Van Vlierberghe P, Ferrando A,. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest. 2012; 122: 3398-3406.
104. Patrick K, Vora A,. Update on biology and treatment of T-cell acute lymphoblastic leukaemia. Curr Opin Pediatr. 2015; 27: 44-49.
105. De Keersmaecker K, Ferrando AA,. TLX1-induced T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2011; 17: 6381-6386.
106. Van Vlierberghe P, Palomero T, Khiabanian H, et al., PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 2010; 42: 338-342.
107. Van der Meulen J, Sanghvi V, Mavrakis K, et al., The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood. 2015; 125: 13-21.
108. Weng AP, Ferrando AA, Lee W, et al., Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306: 269-271.
109. Ferrando AA,. The role of NOTCH1 signaling in T-ALL [serial online]. Hematology Am Soc Hematol Educ Program. 2009; 2009: 353-361.
110. Paganin M, Ferrando A,. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev. 2011; 25: 83-90.
111. Coustan-Smith E, Mullighan CG, Onciu M, et al., Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009; 10: 147-156.
112. Patrick K, Wade R, Goulden N, et al., Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014; 166: 421-424.
113. Zhang J, Ding L, Holmfeldt L, et al., The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481: 157-163.
114. Treanor LM, Zhou S, Janke L, et al., Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J Exp Med. 2014; 211: 701-713.
115. Maude SL, Dolai S, Delgado-Martin C, et al., Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015; 125: 1759-1767.
116. Zenatti PP, Ribeiro D, Li W, et al., Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet. 2011; 43: 932-939.
117. Lo Nigro L, Mirabile E, Tumino M, et al., Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia. Leukemia. 2013; 27: 2419-2421.
118. Locatelli F, Schrappe M, Bernardo ME, Rutella S,. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012; 120: 2807-2816.
119. Teachey DT, Hunger SP,. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol. 2013; 162: 606-620.
120. Mullighan CG, Phillips LA, Su X, et al., Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008; 322: 1377-1380.
121. Ma X, Edmonson M, Yergeau D, et al., Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia [serial online]. Nat Commun. 2015; 6: 6604.
122. Bhojwani D, Kang H, Moskowitz NP, et al., Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2006; 108: 711-717.
123. Yang JJ, Cheng C, Yang W, et al., Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA. 2009; 301: 393-403.
124. Mullighan CG, Zhang J, Kasper LH, et al., CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011; 471: 235-239.
125. Malinowska-Ozdowy K, Frech C, Schonegger A, et al., KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia [published online ahead of print April 28, 2015 ]. Leukemia. doi: 10.1038/leu.2015.107.
126. Gang EJ, Hsieh YT, Pham J, et al., Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene. 2014; 33: 2169-2178.
127. Tzoneva G, Perez-Garcia A, Carpenter Z, et al., Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med. 2013; 19: 368-371.
128. Meyer JA, Wang J, Hogan LE, et al., Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet. 2013; 45: 290-294.
129. Yang JJ, Bhojwani D, Yang W, et al., Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood. 2008; 112: 4178-4183.
130. Mar BG, Bullinger LB, McLean KM, et al., Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia [serial online]. Nat Commun. 2014; 5: 3469.
131. Bhatla T, Jones CL, Meyer JA, Vitanza NA, Raetz EA, Carroll WL,. The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions. J Pediatr Hematol Oncol. 2014; 36: 413-418.
132. Irving J, Matheson E, Minto L, et al., Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014; 124: 3420-3430.
133. Conter V, Valsecchi MG, Parasole R, et al., Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood. 2014; 123: 1470-1478.
134. Paganin M, Fabbri G, Conter V, et al., Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia. J Clin Oncol. 2014; 32: 3553-3558.
135. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al., Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998; 352: 1731-1738.
136. Peterson JK, Houghton PJ,. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer. 2004; 40: 837-844.
137. Norris RE, Adamson PC,. Challenges and opportunities in childhood cancer drug development. Nat Rev Cancer. 2012; 12: 776-782.
138. Arico M, Conter V, Valsecchi MG, et al., Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study. Haematologica. 2005; 90: 1186-1191.